Clinical trial
Prevention of Asthma Relapse After Discharge From Emergency
NCT00326053 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00326053 |
|---|---|
| Title | Prevention of Asthma Relapse After Discharge From Emergency |
| Official title | A Comparison of Budesonide/Formoterol Turbuhaler® 160/4.5 µg 2 Inhalations BID Plus as Needed to Budesonide Turbuhaler® 320 µg 2 Inhalations BID Plus Terbutaline Turbuhaler® 0.4 mg as Needed for the Prevention of Asthma Relapse |
| Acronym | PARADE |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Budesonide/formoterol |
| Enrollment | 600 |
| Start date | May 1, 2006 |
| Completion | May 1, 2007 |
| First posted | May 16, 2006 |
| Last update posted | Jan 24, 2011 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: